Lumen Bioscience, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-04-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.lumen.bio
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06556940
- Locations
- 🇦🇺
Coastal Digestive Health Research Institute Pty Ltd, Maroochydore, Australia
Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia
- Conditions
- Travelers Diarrhea
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT06363890
- Locations
- 🇦🇺
AK Clinical Research, Melbourne, Australia
A Study to Determine the Tolerability of Intranasal LMN-301
- Conditions
- COVID-19
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06030414
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
LMN-201 for Prevention of C. Difficile Infection Recurrence
- Conditions
- Clostridioides Difficile Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 375
- Registration Number
- NCT05330182
- Locations
- 🇺🇸
Kaiser Permanente, Escondido, California, United States
🇺🇸Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸Gastroenterology Center of Connecticut, Hamden, Connecticut, United States
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
- Conditions
- C. Diff. Infections
- Interventions
- Biological: LMN-201 Anti-toxin B VHH-1Biological: LMN-201 Anti-toxin B VHH-2Biological: LMN-201 Anti-toxin B VHH-3Biological: LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04893239
- Locations
- 🇦🇺
Wesley Medical Research Limited, Auchenflower, Queensland, Australia
🇦🇺Coastal Digestive Health, Maroochydore, Queensland, Australia
🇦🇺Coral Sea Clinical Research Institute, North Mackay, Queensland, Australia
- Prev
- 1
- 2
- Next